

Brief Report

Insulin Placement Properly in the Portal Vein

E. Dennis Murphy

Department of Medicine, NorthShore University Health System University of Chicago Pritzker School of Medicine, USA

***Corresponding author:** E Dennis Murphy, Department of Medicine, NorthShore University Health System University of Chicago Pritzker School of Medicine 2650 Ridge Avenue, Evanston IL 6020, USA Email: EDMurphy77@sbcglobal.net

Citation: Murphy ED (2017) Insulin Placement Properly in the Portal Vein. J Diabetes Treat 2017: J108

Received Date: 1 October, 2017; **Accepted Date:** 9 March, 2017; **Published Date:** 16 March, 2017

When injected insulin was first given to patients with diabetes nearly a century ago, it represented a milestone in medical care. Contrasts between this exogenous insulin placed subcutaneously, and endogenous insulin secreted into the portal system has long been clear [1]. Insulin placement causes higher peripheral insulin and lower portal insulin levels in patients with insulin dependent diabetes than in non-diabetic patients [2].

Insulin in high peripheral levels is associated with undesirable side effects upon the vascular system [3,4], contributes to ischemic heart disease [5], as well as having association with certain cancer risks [6].

When insulin is placed directly or indirectly into the portal system in laboratory animals or in the clinical setting, the extent of peripheral insulin increase is diminished and portal insulin levels are increased [7]. Each of these changes more nearly brings subsequent insulin levels closer to the normal range.

In humans insulin has been placed in isolated bowel wall loops in catheters placed in the portal venous system [8]. With each approach, portal insulin levels are higher and peripheral insulin levels lower than in peripheral insulin injected animals.

As well, in humans intraperitoneal insulin has been given with similar results. In the latter setting, however hepatic steatosis and steatonecrosis have evolved in renal failure suggesting that this placement of insulin has unacceptable side effects. The appeal of oral insulin administration, both of simplicity and of delivery to the portal system is obvious. Gastric breakdown and failure of insulin absorption have thus far prevented effective oral administration [10-11].

So what shall we do? To begin and to end: evaluate insulin administration and delivery directly by injection into the portal system and indirectly thereto from the gut, by oral delivery, in a continuing effort to imitate non diabetic insulin levels in the patient with diabetes.

References

1. Madison LL, Unger RH (1958) The physiologic significance of the secretion of endogenous insulin into the portal circulation. I, comparison of the effects of glucagon-free insulin administered via the portal vein and via a peripheral vein on the magnitude of hypoglycemia and peripheral glucose utilization. *JCI* 67: 631-639.
2. Felig P (1974) Insulin rates and routes of delivery. *N Engl J Med* 291:1031-1032.
3. Stolar MW (1988) Atherosclerosis in diabetes: the role of hyperinsulinemia. *Metabolism* 37:1-9.
4. Salonen JT, Lakka TA, Lakka HM, Valkonen VP, Everson SA, et al. (1998) Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. *Diabetes* 1998 47:270-275.
5. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, et al. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. *N Engl J Med* 334:952-957.
6. Dankner R, Shanik MH, Keinan-Boker L, Cohen C, Chetrit A (2012) Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients. *Diabetes Care*:1538-1543.
7. Murphy ED (2014) Insulin: appropriate placement in the portal vein. *Advances in Diabetes and Metabolism* 2:1-3.
8. Murphy ED (1979) Portal vein insulin placement via cutaneous bowel loop wall injection. *Diabetes*, Abstract Reproduction Annual Meeting.
9. Wanless IR, Bargman JM, Oreopoulos DG, Vas SI (1989) Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. *Mod Pathol* 2:66-74.
10. Fonte P, Arújo F, Reis S, Sarmiento B (2013) Oral insulin delivery: How far are we?. *J. Diabetes Sci Technol.* 7:520-531.
11. HE H, Ye J, Sheng J, Wang J, Huang Y, et al. (2007) Overcoming oral insuling delivery barriers: application of cel penetrating peptide and silica-based nanoporous compowsite. *Chem SciEng*7: 9-19